LNKMutations inJAK2Mutation–Negative Erythrocytosis
Authors:
- Terra L. LashoTLTerra L. Lasho
- Animesh PardananiAPAnimesh Pardanani
- Ayalew TefferiATAyalew Tefferi
- 16 September 2010
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (12) , 1189-1190
Abstract
Erythrocytosis occurring in association with a subnormal serum erythropoietin level is indicative of underlying erythropoietin-independent erythropoiesis, in patients with polycythemia vera, or erythropoietin-hypersensitive erythropoiesis, in patients with congenital erythrocytosis related to an erythropoietin-receptor mutation.1 Activating Janus kinase 2 (JAK2) mutations are found in approximately 99% of patients with polycythemia vera.2 It is currently assumed that other mutations relevant to JAK signaling contribute to the pathogenesis of JAK2 mutation–negative polycythemia vera or “idiopathic erythrocytosis” in patients with a subnormal serum erythropoietin level.Keywords
This publication has 5 references indexed in Scilit:
- Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasmsBlood, 2010
- Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significanceEuropean Journal of Haematology, 2009
- The complete evaluation of erythrocytosis: congenital and acquiredLeukemia, 2009
- Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617FJournal of Leukocyte Biology, 2009
- Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia veraLeukemia, 2007